AI
CSTL icon

Atom Investors’s Castle Biosciences CSTL Stock Holding History

Atom Investors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,827
Closed -$224K – 628
2025
Q3 		$224K Buy
+9,827
New +$200K 0.02% 492

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Atom Investors's CSTL Position: Q4 2025 in Review

Atom Investors sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 9,827 shares — an estimated $224K sold.

Atom Investors first reported a position in CSTL in Q3 2025 and held it in 1 quarter. The position peaked at $224K in Q3 2025. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • Atom Investors reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 9,827 Castle Biosciences shares in Q4 2025, an estimated $224K.
  • Atom Investors first reported a position in Castle Biosciences in Q3 2025 and held it in 1 quarter.
  • Atom Investors's Castle Biosciences position peaked at $224K in Q3 2025.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.